Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.

Julio A Lamprea-Montealegre^1,2,3, Erin Madden^2,3, Sri Lekha Tummalapalli^2,4, Carmen Peralta^1,2,3,5, Torsten B Neilands^1,6, Paola K Garcia⁷, Anthony Muiru^1,2, Leah Karliner^1,6, Michael G Shlipak^1,2,3, Michelle M Estrella^1,2,3

¹Department of Medicine, University of California, San Francisco.

²Kidney Health Research Collaborative, University of California, San Francisco.

³San Francisco VA Health Care System, San Francisco, California.

⁴Division of Healthcare Delivery Science & Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.

⁵Cricket Health Inc, San Francisco, California.

⁶San Francisco Center for Aging in Diverse Communities and the Multiethnic Health Equity Research Center, University of California, San Francisco.

⁷Division of Nephrology, Department of Medicine, Pontificia Universidad Javeriana School of Medicine, Bogotá, Colombia.

PubMed PMC DOI PDF

Abstract

IMPORTANCE: Novel therapies for type 2 diabetes can reduce the risk of cardiovascular disease and chronic kidney disease progression. The equitability of these agents' prescription across racial and ethnic groups has not been well-evaluated. OBJECTIVE: To investigate differences in the prescription of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Cricket Health
affiliation

Other Funding

NHLBI NIH HHS(K99 HL157721)
United States
NIA NIH HHS(P30 AG015272)
United States
NIA NIH HHS(K24 AG067003)
United States
NIDDK NIH HHS(K23 DK119562)
United States
NIMH NIH HHS(P30 MH062246)
United States

MeSH Terms

Adult0Aged0Cross-Sectional Studies0Diabetes Mellitus, Type 2*Ethnicity0Female0Health Equity0Healthcare Disparities*Humans0Hypoglycemic Agents0Male0Practice Patterns, Physicians'0Prescriptions*Professional Practice0Racial Groups0Sodium-Glucose Transporter 2 Inhibitors*United States0Veterans Health*Glucagon-Like Peptide-1 Receptor Agonists*

Article Info

PMID: 36066519
PMCID: PMC9449794
DOI: 10.1001/jama.2022.13885

How to Cite

Lamprea-Montealegre JA et al. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA2022;328(9):861-871. doi:10.1001/jama.2022.13885

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.